GSKN Stock Chart & Stats
$882.00
$0.00(0.00%)
At close: 4:00 PM EDT
$882.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$666.00 - $1,169.96
Previous CloseN/A
Volume0.00
Average Volume (3M)4.00
Market Cap
$1.81T
Enterprise Value$125.93K
Total Cash (Recent Filing)$3.09B
Total Debt (Recent Filing)$18.13B
Price to Earnings (P/E)16.1
Beta0.14
Next Earnings
Oct 28, 2026EPS Estimate
24.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.40
Shares Outstanding2,022,697,600
10 Day Avg. Volume4
30 Day Avg. Volume4
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)4.51
Price to Sales (P/S)2.26
P/FCF Ratio12.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$1,187.34Price Target Upside34.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)82.68
Revenue Forecast (FY)$784.78B
Bulls Say, Bears Say
Bulls Say
High Margins & Improving Cash GenerationGSK’s current margin profile and improving free cash flow (~$7.0B TTM) provide durable internal funding for R&D, dividend support and strategic actions. Sustained cash generation underpins capacity to invest in late‑stage assets and manage returns even amid industry headwinds over the next several quarters.
Late‑stage Pipeline & 'Accelerate Growth' ReallocationThe Accelerate Growth programme restructures resources toward late‑stage oncology, respiratory, hepatology and vaccines while targeting GBP1.9B of annual savings. This strategic reallocation to higher‑value specialty R&D and a new Cambridge R&D hub materially strengthens medium‑term growth runway and portfolio resilience.
ViiV HIV Franchise Clinical MomentumPositive Phase III adolescent data for long‑acting CAB+RPV LA reinforces ViiV’s competitive position in HIV care, expands addressable populations and supports durable revenue streams. Enhanced adherence and differentiated therapy formats improve commercial defensibility and long‑term franchise value.
Bears Say
Elevated LeverageGSK’s balance sheet shows meaningful leverage that constrains flexibility: higher interest costs and a net‑debt/EBITDA ratio above management targets limit headroom for large M&A or aggressive buybacks. Deleveraging plans reduce near‑term optionality and remain a focus for the next several quarters.
Earnings And Cash‑flow VolatilityPast swings in earnings and FCF reduce forecast reliability and heighten execution risk for strategic plans. Even with current FCF improvement, variability driven by working capital, timing of receipts and product mix could stress payouts or R&D funding if adverse events recur over the coming 2–6 months.
Dolutegravir Patent Expiry ExposureGSK explicitly cites the dolutegravir LoE as a near‑to‑medium term headwind. Patent expiry risks rapid generic entry and margin pressure on a core product; mitigation depends on timely launches and commercialization of late‑stage assets and realized cost savings, a multi‑quarter execution challenge.
GlaxoSmithKline News
GSKN FAQ
What was GlaxoSmithKline’s price range in the past 12 months?
GlaxoSmithKline lowest stock price was $666.00 and its highest was $1169.96 in the past 12 months.
What is GlaxoSmithKline’s market cap?
GlaxoSmithKline’s market cap is $1.81T.
When is GlaxoSmithKline’s upcoming earnings report date?
GlaxoSmithKline’s upcoming earnings report date is Oct 28, 2026 which is in 83 days.
How were GlaxoSmithKline’s earnings last quarter?
GlaxoSmithKline released its earnings results on Jul 28, 2026. The company reported $23.245 earnings per share for the quarter, beating the consensus estimate of $21.478 by $1.767.
Is GlaxoSmithKline overvalued?
According to Wall Street analysts GlaxoSmithKline’s price is currently Undervalued.
Does GlaxoSmithKline pay dividends?
GlaxoSmithKline does not currently pay dividends.
What is GlaxoSmithKline’s EPS estimate?
GlaxoSmithKline’s EPS estimate is 24.13.
How many shares outstanding does GlaxoSmithKline have?
GlaxoSmithKline has 2,022,697,600 shares outstanding.
What happened to GlaxoSmithKline’s price movement after its last earnings report?
GlaxoSmithKline reported an EPS of $23.245 in its last earnings report, beating expectations of $21.478. Following the earnings report the stock price went up 7.71%.
Which hedge fund is a major shareholder of GlaxoSmithKline?
Currently, no hedge funds are holding shares in MX:GSKN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GlaxoSmithKline Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$1,187.34 (34.62% Upside)
$1,187.34 (34.62% Upside)
Blogger Sentiment
Bullish
MX:GSKN Sentiment 83%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.29%
12-Months-Change
Fundamentals
Return on Equity
3.53%
Trailing 12-Months
Asset Growth
0.91%
Trailing 12-Months
Company Description
GlaxoSmithKline
GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally. The company's operations are organized into two key divisions: Commercial Operations and Total R&D. Its extensive vaccine portfolio includes immunizations against shingles, meningitis, respiratory syncytial virus (RSV), seasonal and pandemic influenza, and polio. Beyond preventative care, GSK provides diverse therapeutic products covering critical areas such as HIV, oncology, respiratory and immunology conditions, and other specialized medical fields. This also encompasses inhaled treatments for chronic respiratory ailments like asthma and chronic obstructive pulmonary disease (COPD), along with antibiotics for various infections. Innovation at GSK is frequently driven by strategic partnerships. Notable collaborations include an agreement with CureVac to advance mRNA-based influenza vaccines, and alliances with Wave Life Sciences and Elsie Biotechnologies focused on developing oligonucleotide platforms. Furthermore, GSK has established two distinct strategic collaborations with Relation to progress therapeutics for fibrotic diseases and osteoarthritis. The company is also engaged in a multi-target strategic alliance aimed at developing pioneering treatments for individuals suffering from Parkinson's disease, and a partnership with Flagship Pioneering to identify novel medicines and vaccines.
GSKN Company Deck
GSKN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a predominantly positive tone: strong operational execution produced record infrastructure results, marked improvements in marketing, accretive M&A (Chauvin), improved throughput and cash flow, and concrete balance sheet and cost-savings actions. Challenges were primarily industry-wide and temporary — export volatility, vessel/freight constraints, short-term storage market dynamics, and leverage that management expects to normalize in early 2027. Management expressed confidence in organic growth opportunities and reiterated targets for deleveraging and sustainable cost savings.View all MX:GSKN earnings summariesGSKN Stock 12 Month Forecast
Average Price Target
$1,187.34
▲(34.62% Upside)